Clal Insurance Enterprises Holdings Ltd Has $69.25 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Clal Insurance Enterprises Holdings Ltd grew its position in Eli Lilly and Company (NYSE:LLY) by 5.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 89,704 shares of the company’s stock after purchasing an additional 4,904 shares during the period. Clal Insurance Enterprises Holdings Ltd’s holdings in Eli Lilly and Company were worth $69,251,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the stock. SBI Securities Co. Ltd. bought a new position in Eli Lilly and Company during the fourth quarter valued at approximately $15,415,000. Jones Financial Companies Lllp raised its position in Eli Lilly and Company by 30.4% during the fourth quarter. Jones Financial Companies Lllp now owns 113,685 shares of the company’s stock valued at $87,765,000 after acquiring an additional 26,493 shares in the last quarter. SRS Capital Advisors Inc. raised its position in Eli Lilly and Company by 8.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 2,673 shares of the company’s stock valued at $2,063,000 after acquiring an additional 208 shares in the last quarter. Bailard Inc. raised its position in Eli Lilly and Company by 16.5% during the fourth quarter. Bailard Inc. now owns 13,045 shares of the company’s stock valued at $10,071,000 after acquiring an additional 1,852 shares in the last quarter. Finally, Norden Group LLC raised its position in Eli Lilly and Company by 77.5% during the fourth quarter. Norden Group LLC now owns 6,993 shares of the company’s stock valued at $5,399,000 after acquiring an additional 3,054 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 1.7 %

Shares of Eli Lilly and Company stock opened at $920.44 on Friday. The company’s fifty day simple moving average is $814.88 and its 200-day simple moving average is $848.69. The company has a market cap of $872.73 billion, a price-to-earnings ratio of 78.60, a PEG ratio of 1.40 and a beta of 0.42. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its board has authorized a share buyback program on Monday, December 9th that allows the company to buyback $15.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.65%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s payout ratio is currently 51.24%.

Analysts Set New Price Targets

LLY has been the topic of several recent research reports. Truist Financial raised their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Wolfe Research assumed coverage on shares of Eli Lilly and Company in a research report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price objective on the stock. Wells Fargo & Company dropped their price target on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Finally, Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,000.28.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.